Anti-amyloid therapy for Alzheimer’s disease: the time has come

Chairs: Katsuya Urakami
Department of Dementia Prevention, School of Health Science, Faculty of Medicine, Tottori University, Japan
Atsushi Iwata
Tokyo Metropolitan Geriatric Hospital, Japan

HT-01-1
Gantenerumab in early symptomatic Alzheimers Disease
Janice W. Smith
Roche Products Ltd, UK

HT-01-2
TRAILBLAZER-ALZ-4: Comparing donanemab to aducanumab in early, symptomatic Alzheimer's disease
Stephane Epelbaum
Eli Lilly and Company, USA

HT-01-3
Development of Therapeutics in Alzheimer's disease
Yasuo Toda
Biogen, Japan

HT-01-4
CLARITY AD: A Global Phase 3 Trial of Lecanemab in Early Alzheimer's Disease
Jin Zhou
Eisai, Inc., USA

Nominal supported by: Japan Society for Dementia Research

Cutting edge of development in stroke therapy
How does the researcher achieve the translational research?

Chairs: Tetsuro Ago
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
Ryota Tanaka
Stroke Center and Division of Neurology, Department of Medicine, Japan

HT-02-1
Development of novel thrombolytic agents using SMTP
Kuniyasu Niizuma
Department of Neurosurgical Engineering and Translational Neuroscience, Graduate School of Biomedical Engineering, Tohoku University, Japan / Department of Neurosurgical Engineering and Translational Neuroscience, Tohoku University Graduate School of Medicine, Japan / Department of Neurosurgery, Tohoku University Graduate School of Medicine, Japan

HT-02-2
Development of an efferocytosis drug for the treatment of cerebral ischemia
Akira Shibuya
Center for Innovative Drug Discovery and Faculty of Medicine, University of Tsukuba, Japan
| HT-02-3 | Targeting the moyamoya disease susceptibility gene RNF213 as a therapeutic strategy for stroke  
Masafumi Ihara  
Department of Neurology, National Cerebral and Cardiovascular Center, Japan |
|---------|----------------------------------------------------------------------------------|
| HT-02-4 | Development of vaccines in ischemic stroke  
- Focusing on anti-thrombotic vaccines against S100A9  
Munehisa Shimamura  
Department of Gene & Stem Cell Regenerative Therapy, Osaka University, Japan / Department of Neurology, Osaka University, Japan |

<table>
<thead>
<tr>
<th>HT-03</th>
<th>Hot Topics 03</th>
<th>Web</th>
<th>En</th>
</tr>
</thead>
</table>
| All Roads Lead to Cure  
- from basic researches towards clinical trials for ataxia  
Chairs: Yoshio Ikeda  
Department of Neurology, Gunma University Graduate School of Medicine, Japan  
Yuji Takahashi  
National Center of Neurology and Psychiatry, Japan |
| HT-03-1 | The ATXN2 complex as a therapeutic target for spinocerebellar ataxias and ALS  
Stefan M M. Pulst  
University of Utah, USA |
| HT-03-2 | Therapeutic approaches for non-coding repeat expansion diseases  
Yoshio Ikeda  
Department of Neurology, Gunma University Graduate School of Medicine, Japan |
| HT-03-3 | Pathophysiology and therapeutic strategies for spinocerebellar ataxia type 42  
Fumiaki Tanaka  
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan |
| HT-03-4 | Multiple system atrophy: from genetics to clinical trials  
Shoji Tsuji  
International University of Health and Welfare, Japan / Department of Neurology, The University of Tokyo Hospital, Japan |
HT-04 Hot Topics 04

June 1 (Thu) 8:00 ~ 9:30  Room 05 (Makuhari Messe International Conference Hall 3F 304)

MS brain inflammation; to B or not to B that is the question
Chairs: Kazumasa Yokoyama  
Tousei center for neurological diseases, Japan
Noriko Isobe  
Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Japan

HT-04-1 Brain Inflammation in MS; Should It be B-Cell therapy? 
From the viewpoint of T cells
Kazumasa Yokoyama  
Tohsei center for neurological diseases, Japan / Department of Neurology Juntendo University, Japan

HT-04-2 Contribution of B cells in MS brain inflammation
Koji Shinoda  
Department of Neurology, Iizuka Hospital, Japan / Department of Neurology, Kyushu University, Japan

HT-04-3 Neuroinflammation as therapeutic targets based on innate immune system
Izumi Kawachi  
Dept. of Neurology, Brain Research Institute, Niigata University, Japan / Medical Education Center, Niigata University School of Medicine, Japan

HT-04-4 Glial CNS inflammation and its treatment
Hideyuki Takeuchi  
Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan

HT-05 Hot Topics 05

June 1 (Thu) 15:35 ~ 17:35  Room 02 (Makuhari Messe International Conference Hall 2F International Conference Room)

Disease-modifying treatment of PD: 
What is the rate-limiting factor of drug discovery?
Chairs: Atsushi Takeda  
National Hospital Organization Sendai Nishitaga Hospital, Japan
Noriko Nishikawa  
Department of Neurology, Juntendo University School of Medicine, Japan

HT-05-1 Synuclein-targeting therapies in PD: 
what do we know and where are we headed? 
Takafumi Hasegawa  
Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Japan

HT-05-2 What triggers Parkinson's disease? 
Approach from familial form for drug discovery
Yutaka Oji  
Department of Neurology, Juntendo University School of Medicine, Japan
HT-05-3 Updates of disease biomarkers of Parkinson’s disease
Chin-Hsien Lin
National Taiwan University Hospital, Taiwan

HT-05-4 Issues in clinical trials of disease-modifying therapies for Parkinson’s disease
Thomas Foltynie
UCL Institute of Neurology, UK / National Hospital for Neurology & Neurosurgery, UK

HT-06 Hot Topics 06
June 2 (Fri) 8:00 ~ 9:30 Room 11 (Tokyo Bay Makuhari Hall 2F No.3, 4)

Development of the basic research using human brain tissues
Chairs: Masaki Takao
National Center of Neurology and Psychiatry (NCNP) National Center Hospital, Japan
Maya Mimuro
Pathology Division, Mie University Hospital, Japan

HT-06-1 Toward elucidation of neuropathological basis of bipolar disorder
Tadafumi Kato
Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Japan

HT-06-2 Drug transporter study at central nervous system barrier using human postmortem brain
Yasuo Uchida
Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan

HT-06-3 Atomic structures of pathological protein filaments in neurodegenerative diseases
Masato Hasegawa
Tokyo Metropolitan Institute of Medical Science, Japan

HT-06-4 Human Postmortem Brain Study of Tauopathy with a Focus on ALS/PDC in the Kii Peninsula
Satoru Morimoto
Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institution of Gerontology, Japan / Department of Physiology, Keio University School of Medicine, Japan / Department of Oncologic Pathology, Mie University, Japan

Nominal supported by: The Japanese Society of Neuropathology
Migraine: Pathophysiology and the paradigm shift of management

Chairs: Hisaka Igarashi
Headache Care Unit, Department of Internal Medicine, Fujitsu Clinic, Japan
Takao Takeshima
Neurology, Tominaga Hospital, Japan

HT-07-1 Central mechanism in migraine pathogenesis
Mamoru Shibata
Tokyo Dental College Ichikawa General Hospital, Japan

HT-07-2 Peripheral mechanism and key players in migraine
Tsubasa Takizawa
Department of Neurology, Keio University School of Medicine, Japan

HT-07-3 CGRP monoclonal antibodies
Daisuke Danno
Tominaga Hospital Headache Center, Japan

HT-07-4 Migraine and Neuromodulation
Noboru Imai
Department of Neurology / Headache Center, Japanese Red Cross Shizuoka Hospital, Japan

HT-07-5 Management of Migraine
Andrew Blumenfeld
The Los Angeles Headache Center, USA